Francis Arena, MD

  • Specialties: Medical Oncology, Hematology
  • Language: English
  • Phone: 516-466-6611

About Me

Conditions and Treatments

anemia, cancer of the soft tissue, prostate cancer, multiple myeloma (MM), bladder cancer, ovarian cancer, leukemia, lung cancer, liver cancer, pancreatic cancer, kidney cancer, colon cancer, breast cancer, blood cancer, melanoma, rectal cancer
Show More Conditions

Credentials

Positions
  • Clinical Associate Professor, Department of Medicine
  • Medical Director, NYU Langone Arena Oncology
Board Certifications
  • American Board of Internal Medicine (Medical Oncology), 1995
  • American Board of Internal Medicine - Internal Medicine, 1978
Education and Training
  • MD from Cornell University, 1975
Departments

Locations and Appointments

View Insurance Plans Accepted
  • Aetna
    • Aetna HMO
    • Aetna Indemnity
    • Aetna Medicare
    • Aetna POS
    • Aetna PPO/EPO
  • Agewell
    • Agewell
  • Alphacare
    • Alphacare
  • Cigna
    • Cigna EPO/POS
    • Cigna PPO
  • ElderPlan
    • ElderPlan
  • Empire Blue Cross Blue Shield
    • Empire Blue Cross Blue Shield EPO
    • Empire Blue Cross Blue Shield HMO
    • Empire Blue Cross Blue Shield Indemnity
    • Empire Blue Cross Blue Shield MediBlue
    • Empire Blue Cross Blue Shield POS
    • Empire Blue Cross Blue Shield PPO
    • Empire Blue Cross Blue Shield Pathways, Enhanced
  • Fidelis
    • Fidelis Child Health
    • Fidelis Essential
    • Fidelis Exchange
    • Fidelis Family Health
    • Fidelis Medicaid
    • Fidelis Medicare
  • GHI
    • GHI CBP
  • HIP
    • HIP Access I
    • HIP Access II
    • HIP Child Health
    • HIP EPO/PPO
    • HIP Essential
    • HIP Family Health
    • HIP HMO
    • HIP Medicaid
    • HIP Medicare
    • HIP POS
  • HealthSmart
    • HealthSmart (WTC)
  • Healthfirst
    • Healthfirst
    • Healthfirst Essential
  • ICSNY
    • Independent Care System New York
  • Local 1199
    • Local 1199 PPO
  • MagnaCare
    • MagnaCare PPO
  • Medicare
    • Medicare
  • MultiPlan/PHCS
    • MultiPlan/PHCS PPO
  • NYS
    • NYS Empire Plan
  • Oscar
    • Oscar
  • Oxford
    • Oxford Freedom
    • Oxford Liberty
    • Oxford Medicare
  • PHP
    • PHP
  • Queens Medicare
    • Queens Medicare
  • Railroad Medicare
    • Railroad Medicare
  • Tricare
    • Tricare
  • UHC
    • UnitedHealthcare Community & State Plan
    • UnitedHealthcare Core and Charter
    • UnitedHealthcare EPO
    • UnitedHealthcare HMO
    • UnitedHealthcare Medicare
    • UnitedHealthcare POS
    • UnitedHealthcare PPO
    • UnitedHealthcare Top Tier
  • UPN
    • UPN Elite
  • VNS
    • Visiting Nurse Service (VNS) Medicare
  • Village Caremax
    • Village Caremax
NYU Langone Arena Oncology

1999 Marcus Avenue
North New Hyde Park, NY 11042

Contact

Phone: 516-466-6611

NYU Langone Arena Oncology

157-02 Cross Bay Boulevard, Suite 204
Queens, NY 11414

Contact

Phone: 718-845-9616

NYU Langone Arena Oncology

715 Roanoke Avenue, Suite 1
Riverhead, NY 11901

Contact

Phone: 631-591-4474

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

Publications

  • CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

    Chiorean, E G; Von Hoff, D D; Reni, M; Arena, F P; Infante, J R; Bathini, V G; Wood, T E; Mainwaring, P N; Muldoon, R T; Clingan, P R; Kunzmann, V; Ramanathan, R K; Tabernero, J; Goldstein, D; McGovern, D; Lu, B; Ko, A Chiorean, E G; Von Hoff, D D; Reni, M; Arena, F P; Infante, J R; Bathini, V G; Wood, T E; Mainwaring, P N; Muldoon, R T; Clingan, P R; Kunzmann, V; Ramanathan, R K; Tabernero, J; Goldstein, D; McGovern, D; Lu, B; Ko, A
    Annals of oncology. 2016 Jan 22. 27 (4): 654-660

  • Everolimus plus trastuzumab and vinorelbine for trastuzumab-resistant, taxane-pretreated, HER2+advanced breast cancer: Overall survival results from BOLERO-3 [Meeting Abstract]

    Isaacs, C; O'Regan, R; Xu, B; Masuda, N; Arena, F; Yap, Y-S; Papal, Z; Lang, I; Armstrong, A; Lerzo, G; White, M; Shen, K; Zhang, Y; Jappe, A; Pacaud, LB; Taran, T; Ozguroglu, M Isaacs, C; O'Regan, R; Xu, B; Masuda, N; Arena, F; Yap, Y-S; Papal, Z; Lang, I; Armstrong, A; Lerzo, G; White, M; Shen, K; Zhang, Y; Jappe, A; Pacaud, LB; Taran, T; Ozguroglu, M
    Cancer research. 2016 FEB 15. 76: ?-?

  • Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas

    Ramanathan, R K; Goldstein, D; Korn, R L; Arena, F; Moore, M; Siena, S; Teixeira, L; Tabernero, J; Van Laethem, J-L; Liu, H; McGovern, D; Lu, B; Von Hoff, D D Ramanathan, R K; Goldstein, D; Korn, R L; Arena, F; Moore, M; Siena, S; Teixeira, L; Tabernero, J; Van Laethem, J-L; Liu, H; McGovern, D; Lu, B; Von Hoff, D D
    Annals of oncology. 2016 Jan 22. 27 (4): 648-653

Read All Publications (18)